Literature DB >> 21936027

Cell therapy for fibrotic interstitial pulmonary disease: experimental study.

Rosa M Cabral1, Érika Branco, Márcia Dos S Rizzo, Guilherme J Ferreira, Guilherme B Gregores, Vivian Y Samoto, Angelo J Stopiglia, Paulo C Maiorka, Emerson T Fioretto, Vera L Capelozzi, João B Borges, Susimeire Gomes, Marcelo A Beraldo, Carlos R R Carvalho, Maria A Miglino.   

Abstract

Parte superior do formulário Digite um texto ou endereço de um site ou traduza um documento. The aim of this study is to evaluate the histological changes in lung parenchyma of pigs affected by interstitial lung disease induced after the infusion of bone marrow mononuclear cells (BMMCs). Ten female swines were submitted to pulmonary fibrosis induced by a single dose of intratracheal bleomicine sulfate. Animals were arranged into two groups: Group 1: induced-disease control and Group 2: cell therapy using BMMCs. Both groups were clinically evaluated for 180 days. High-resolution computed tomography (HRCT) was performed at 90 and 180 days. BMMC sampling was performed in cell therapy group at 90 days. Euthanasia was performed, and samples were collected for histology and immunohistochemistry. The 90-days HRCT demonstrated typical interstitial lesions in pulmonary parenchyma similarly to human disease. The 180-days HRCT in Group 1 demonstrated advanced stages of the disease when compared with Group 2. Immunohistochemistry analysis suggests the presence of pre-existent vessels and neoformed vessels as well as predominant young cells in the injured parenchyma of Group 2. Immunohistochemistry analysis suggests that cell therapy would promote a reconstructive response. Histology and HRCT analysis suggest a positive application of swine as a model for a bleomicine inducing of fibrotic interstitial pulmonary disease.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21936027     DOI: 10.1002/jemt.20981

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  6 in total

Review 1.  Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012.

Authors:  Daniel J Weiss
Journal:  Ann Am Thorac Soc       Date:  2013-10

2.  Cell therapy trials for lung diseases: progress and cautions.

Authors:  Daniel J Weiss; Luis A Ortiz
Journal:  Am J Respir Crit Care Med       Date:  2013-07-15       Impact factor: 21.405

3.  Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model.

Authors:  Luai Huleihel; Jacobo Sellares; Nayra Cardenes; Diana Álvarez; Rosa Faner; Koji Sakamoto; Guoying Yu; Maria G Kapetanaki; Naftali Kaminski; Mauricio Rojas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-04-06       Impact factor: 5.464

4.  Experimental Actinobacillus pleuropneumoniae challenge in swine: comparison of computed tomographic and radiographic findings during disease.

Authors:  Carsten Brauer; Isabel Hennig-Pauka; Doris Hoeltig; Falk F R Buettner; Martin Beyerbach; Hagen Gasse; Gerald-F Gerlach; Karl-H Waldmann
Journal:  BMC Vet Res       Date:  2012-04-30       Impact factor: 2.741

5.  Anti-inflammatory and anti-fibrotic effects of intravenous adipose-derived stem cell transplantation in a mouse model of bleomycin-induced interstitial pneumonia.

Authors:  Takuya Kotani; Ryota Masutani; Takayasu Suzuka; Katsuhiro Oda; Shigeki Makino; Masaaki Ii
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

6.  The Effect of Gender on Mesenchymal Stem Cell (MSC) Efficacy in Neonatal Hyperoxia-Induced Lung Injury.

Authors:  Ibrahim Sammour; Santhosh Somashekar; Jian Huang; Sunil Batlahally; Matthew Breton; Krystalenia Valasaki; Aisha Khan; Shu Wu; Karen C Young
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.